Trisodium 7-[[4-chloro-6-[ethyl[3-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-4-hydroxy-3-[(4-methoxy-2-sulphonatophenyl)azo]naphthalene-2-sulphonate

Endpoint summary

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From July 01, 1982 to July 15, 1982

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Principles of method if other than guideline:

The acute oral toxicity of the substance was conducted in male and female ICR mice through oral gavage of a single dose at concentrations of 0, 2500 and 5000 mg/kg bw. The mortality, clinical signs and body weights were examined for 2 weeks thereafter. Thereafter, all surviving animals were necropsied for gross pathological examination of main tissues and organs.

GLP compliance:

yes

Limit test:

no

Species:

mouse

Strain:

ICR

Sex:

male/female

Details on test animals or test system and environmental conditions:

Origin: Charles River Japan Inc.
Acclimatization: at least 7 d
Body weight at start for males: 26 - 31 g and for females: 21 - 25 g
Age: ca. 5 weeks
Temperature and relative humidity: 23 +/- 1°C and 60 +/- 10%, respectively
Food: CE-2 type, ad libitum (withdrawal from about 20 h before to 3-4 h after treatment)
Water: tap water, ad libitum

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

The test substance appropriately diluted with distilled water was orally administered into the stomach by using a glass syringe attached gastric probe to groups of 10 animals of each sex at rate of 10 or 20 mL per kg bw.

Doses:

0 (negative control), 2500 and 5000 mg/kg bw

No. of animals per sex per dose:

10

Control animals:

yes

Details on study design:

The clinical signs and the mortality were observed at 1/6, 1/2, 1, 2 and 4 hours after administration and daily (at 10 a.m.) for 2 weeks thereafter (observation period). Body weight of each animal was measured at Days 0, 7 and 14. All animals which were alive at the end of the observation period were necropsied for gross pathological examination of main tissues and organs.

Statistics:

- Comparison with the negative controls
T-test for the body weight analysis
Fisher exact test for incidence of gross finding

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 5 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality was observed in the study.

Clinical signs:

No treatment-related clinical signs were observed at any of the tested doses.

Body weight:

There was no test substance-related body weight change.

Gross pathology:

Some abnormal findings such as accentuated lobular pattern in the liver, vesicle or fade area in the kidney, white substance present or retension of urine in the urinary bladder, uterine horn distended with fluid and fluid filled cyst surrounded in the ovary were found in some animals including controls. However, no remarkable test substance-related macroscopic modifications in main tissues and organs were found in any treated animal.

Interpretation of results:

GHS criteria not met

Conclusions:

Under the study conditions, the acute oral LD50 of the substance in mice was determined to be greater than 5000 mg/kg bw.

Executive summary:

A study was conducted to determine the acute oral toxicity of the substance according to an internal method of the laboratory, in compliance with GLP. Male and female ICR mice were administered by oral gavage a single dose of the test substance at 0, 2500 and 5000 mg/kg bw. Rats were fasted 20 h pre-test to 3 -4 h post-application. The clinical signs and mortality were observed at 10 min, 30 min, 1, 2 and 4 h after administration and daily for 2 weeks thereafter. Body weight of each animal was measured at Days 0, 7 and 14. Thereafter, the surviving animals were necropsied for gross pathological examination of main tissues and organs. No mortality and clinical sign were observed during the study. Also, there were no test substance-related body weight changes or macroscopic modifications. Under the study conditions, the acute oral LD50 of the substance in mice was determined to be greater than 5000 mg/kg bw (Hosokawa, 1982).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

5 000 mg/kg bw

Acute toxicity: via inhalation route

Link to relevant study records

Reference

Endpoint:

acute toxicity: inhalation

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

other:

Reason / purpose for cross-reference:

data waiving: supporting information

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Remarks:

RA study

Reason / purpose for cross-reference:

read-across source

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

GLP compliance:

yes (incl. QA statement)

Test type:

fixed dose procedure

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Type of coverage:

occlusive

Vehicle:

unchanged (no vehicle)

Duration of exposure:

24 h

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

Five per sex per group

Control animals:

no

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No

Clinical signs:

None

Interpretation of results:

GHS criteria not met

Conclusions:

Under the study conditions, the acute dermal LD50 of the substance in rats was determined to be greater than 2000 mg/kg bw.

Executive summary:

A study was conducted to determine the acute dermal toxicity of the read-across substance according to OECD Guideline 402, in compliance with GLP. The acute dermal toxicity of was tested in groups of 5 Sprague-Dawley rats/sex at a limit dose level of 2000 mg/kg bw only. No deaths or clinical signs were observed during the entire study period. The skin of the animals was discoloured orange in a large area; development of body weight was not impaired. The animals killed at the end of the observation period showed no macroscopically visible changes. Under the study conditions, the acute dermal LD50 of the substance in rats was determined to be greater than 2000 mg/kg bw (Seeberger, 1999).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Additional information

Acute oral toxicity:

A study was conducted to determine the acute oral toxicity of the substance according to an internal method of the laboratory, in compliance with GLP. Male and female ICR mice were administered by oral gavage a single dose of the test substance at 0, 2500 and 5000 mg/kg bw. Rats were fasted 20 h pre-test to 3 -4 h post-application. The clinical signs and mortality were observed at 10 min, 30 min, 1, 2 and 4 h after administration and daily for 2 weeks thereafter. Body weight of each animal was measured at Days 0, 7 and 14. Thereafter, the surviving animals were necropsied for gross pathological examination of main tissues and organs. No mortality and clinical sign were observed during the study. Also, there were no test substance-related body weight changes or macroscopic modifications. Under the study conditions, the acute oral LD50 of the substance in mice was determined to be  greater than 5000 mg/kg bw (Hosokawa, 1982).

Acute inhalation toxicity:

Waived

Acute dermal toxicity:

A study was conducted to determine the acute dermal toxicity of the read-across substance according to OECD Guideline 402, in compliance with GLP. The acute dermal toxicity of was tested in groups of 5 Sprague-Dawley rats/sex at a limit dose level of 2000 mg/kg bw only. No deaths or clinical signs were observed during the entire study period. The skin of the animals was discoloured orange in a large area; development of body weight was not impaired. The animals killed at the end of the observation period showed no macroscopically visible changes. Under the study conditions, the acute dermal LD50 of the substance in rats was determined to be greater than 2000 mg/kg bw (Seeberger, 1999).

Justification for classification or non-classification

Based on the results of an acute oral and acute dermal toxicity study, the substance does not warrant any classification for acute toxicity according to the EU CLP (EC 1272/2008) criteria.